Biopharma execs give Scott Gottlieb’s nomination for FDA commish (almost) a standing O in Endpoints poll
A big majority of biopharma executives overall are clearly enthusiastic about President Trump’s decision to nominate Scott Gottlieb as the next FDA commissioner.
In our snap poll over the weekend Gottlieb picked up 87% support among the 580 qualified subscribers who voted on the decision, with 504 approving the choice against 76 who largely hated it.
Keep in mind, so far the Trump administration has earned a solid negative rating in the drug development business as execs in overwhelmingly Democratic regions registered their disdain for his travel ban, rejected the notion of gutting regulations and expressed fears that a new approach on H-1B visas could make it much harder to recruit top talent from beyond US borders. Gottlieb, though, looks like a breath of fresh air in an industry that’s been feeling badly choked in Washington, DC for the past two months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.